{"id":"W1963599260","doi":"10.1016/j.clml.2013.05.012","title":"A Critical Review of Trials of First-Line BCR-ABL Inhibitor Treatment in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase","year":2013,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Nilotinib; Dasatinib; Imatinib; Medicine; Tyrosine-kinase inhibitor; Myeloid leukemia; Tyrosine kinase; Internal medicine; Clinical trial; Oncology; Pharmacology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.004199227,0.002731913,0.02306192,0.001246938,0.00009528667,0.0000471161,0.001098008,0.00240804,0.001368203],"category_scores_gemma":[0.01612781,0.001910362,0.004123301,0.002418895,0.001420814,0.0004090618,0.0004469083,0.001430998,0.0003049506],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.096985,"about_ca_system_score_gemma":0.05879513,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001753883,"about_ca_topic_score_gemma":0.0007330528,"domain_scores_codex":[0.9748176,0.002947692,0.01559931,0.002851635,0.001807259,0.001976443],"domain_scores_gemma":[0.9737307,0.0151163,0.005574789,0.003555898,0.0008484778,0.001173834],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"systematic_review","study_design_scores_codex":[0.001276689,0.003796838,0.001453077,0.1351112,0.001332219,0.0006923304,0.00003675393,0.000007868361,0.000001577995,0.0000281229,0.001229721,0.8550336],"study_design_scores_gemma":[0.107361,0.01908886,0.01090631,0.4723766,0.008458938,0.00009980021,0.000007992053,0.0001613787,0.00004101308,0.00002310773,0.3799087,0.00156623],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.03453264,0.9481316,0.00001032854,0.0001165723,0.0006789708,0.01532978,0.0007914922,0.000109342,0.000299253],"genre_scores_gemma":[0.003901159,0.9870268,0.0007945888,0.0002013891,0.001409316,0.003343392,0.00259955,0.0004454562,0.0002783101],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8534674,"threshold_uncertainty_score":0.9995447,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08339020883833671,"score_gpt":0.4046808406504899,"score_spread":0.3212906318121532,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}